Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck BioVentures

Division of Merck & Co. Inc.

Latest From Merck BioVentures

Hanwha In Talks For Enbrel Biosimilar Deal

Germany’s Merck is one of the multinationals said to be in negotiations with the South Korean firm Hanwha over the possible licensing of a biosimilar version of Amgen’s blockbuster rheumatoid arthritis treatment Enbrel and/or related technology.

BioPharmaceutical South Korea

Hanwha Biologics CEO Paul Coleman On Developing Biosimilars In Korea: An Interview With PharmAsia News (Part 1 of 2)

The former Biogen Idec exec sits down to talk about Hanwha’s biosimilars strategy and pipeline, and why its deal fell apart with Merck to develop a biosimilar of Enbrel.

BioPharmaceutical South Korea

Deals Of The Week Wonders: What Does Merck’s Latest Biosimilar Move Really Mean?

Plus a look at Roche/Chiasma, Chiesi/Cornerstone, Eisai/Valeant and more

BioPharmaceutical South Korea

“The Pink Sheet” – Most Notable Stories Of 2012

Developments in off-label enforcement and scrutiny of economic superiority claims, new approaches to R&D, and biosimilars are among issues that captured readers’ attention last year.

BioPharmaceutical Legal Issues
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Merck & Co. Inc.
  • Senior Management
  • Contact Info
  • Merck BioVentures
    One Merck Dr.
    Whitehouse Station, NJ 08889